FDA Brief

Warning letters Drugs

FDA warning letter to

Auto-Chlor System LLC

High riskIssued Dec 20, 2022Posted Jan 10, 2023Division of Pharmaceutical Quality Operations II

Auto-Chlor System LLC made hand sanitizer under poor manufacturing practices and sold it as an unapproved, misbranded new drug.

What happened

FDA inspected Auto-Chlor’s drug manufacturing facility in Hapeville, GA, from July 5 to 18, 2022. FDA found violations of current good manufacturing practice (CGMP, the rules for drug manufacturing), including equipment shared with industrial cleaners, no testing of ethanol for methanol, no process validation, and weak quality oversight. FDA also reviewed the HAND KLEEN label and found the hand sanitizer was an unapproved new drug and misbranded.

What FDA found

  1. The company did not have or follow written procedures for cleaning and maintaining equipment, and FDA observed inadequate cleaning of drug equipment also used for industrial cleaners.

    21 CFR 211.67(b)
  2. The company did not test incoming components for identity and quality, including testing ethanol for methanol, and relied on certificates from unqualified suppliers.

    21 CFR 211.84(d)(1) and (2)
  3. The company used (b)(4) water in drug products without testing it or showing it met purified water and microbial limits.

    21 CFR 211.84(d)(1) and (2)
  4. The company had not validated its hand sanitizer manufacturing processes or qualified its equipment.

    21 CFR 211.100(a)
  5. The quality unit failed to oversee training, active ingredient and microbial testing, stability, annual product reviews, batch records, and investigations.

    21 CFR 211.22
  6. HAND KLEEN is an unapproved new drug and misbranded because its benzethonium chloride formula and labeling do not fit the OTC rules for consumer antiseptic rubs or washes.

    FD&C Act sections 505(a), 502(ee), and 301(d)

What FDA wants

FDA tells Auto-Chlor to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if more time is needed, it must give reasons and a completion schedule. FDA also recommends a qualified CGMP consultant and says to notify FDA before resuming or outsourcing drug manufacturing.

Who should pay attention

  • brands or distributors selling Auto-Chlor hand sanitizer
  • contract manufacturers and private-label firms making OTC hand sanitizers
  • companies sharing equipment between drug and industrial products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk